CorMedix Inc. (CRMD): Price and Financial Metrics
CRMD Price/Volume Stats
| Current price | $5.42 | 52-week high | $7.00 |
| Prev. close | $5.44 | 52-week low | $2.57 |
| Day low | $5.33 | Volume | 32,495 |
| Day high | $5.45 | Avg. volume | 525,357 |
| 50-day MA | $3.98 | Dividend yield | N/A |
| 200-day MA | $3.73 | Market Cap | 297.08M |
CRMD Stock Price Chart Interactive Chart >
CorMedix Inc. (CRMD) Company Bio
CorMedix Inc., a commercial pharmaceutical and medical device company, intends to in-license, develop, and commercialize prophylactic and therapeutic for the prevention and treatment of infectious and inflammatory diseases. The company was founded in 2006 and is based in Bridgewater, New Jersey.
Latest CRMD News From Around the Web
Below are the latest news stories about CORMEDIX INC that investors may wish to consider to help them evaluate CRMD as an investment opportunity.
CorMedix Inc. Announces Appointment of Chief Legal OfficerBERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no |
CorMedix Inc. Announces Partnership With The Leapfrog Group– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog’s Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other pur |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! |
CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients– First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved DefenC |
Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities in Q3 2023Net Loss Widens as Company Prepares for Potential FDA Approval of DefenCath |
CRMD Price Returns
| 1-mo | 41.51% |
| 3-mo | 66.26% |
| 6-mo | 71.52% |
| 1-year | 12.33% |
| 3-year | -28.12% |
| 5-year | -34.62% |
| YTD | 44.15% |
| 2023 | -10.90% |
| 2022 | -7.25% |
| 2021 | -38.76% |
| 2020 | 2.06% |
| 2019 | 12.87% |
Continue Researching CRMD
Want to do more research on CorMedix Inc's stock and its price? Try the links below:CorMedix Inc (CRMD) Stock Price | Nasdaq
CorMedix Inc (CRMD) Stock Quote, History and News - Yahoo Finance
CorMedix Inc (CRMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...